Chromatographia

, 70:1417 | Cite as

Simultaneous Determination of Ebastine and Its Active Metabolite (Carebastine) in Human Plasma Using LC–MS–MS

  • Sheng Feng
  • Ji Jiang
  • Peng Wang
  • Dongyang Liu
  • Pei Hu
Full Short Communication

Abstract

A sensitive and rapid LC–MS–MS method was developed for the simultaneous determination of ebastine and carebastine in human plasma. Solid-phase extraction was used to isolate the compounds from the biological matrix followed by separation on a Symmetry C18 column under isocratic conditions. The mobile phase was 10 mM ammonium formate in water/acetonitrile (40:60, v/v). Detection was carried out using a triple-quadrupole mass spectrometer in positive electrospray ionization and multiple reaction monitoring mode. The method was fully validated over the concentration range of 0.1–10 ng mL−1 for ebastine and 0.2–200 ng mL−1 for carebastine in human plasma, respectively. The lower limit of quantification (LLOQ) was 0.1 ng mL−1 for ebastine and 0.2 ng mL−1 for carebastine. For ebastine and carebastine inter- and intra-day precision (CV%) and accuracy values were all within ±15% and 85–115%, respectively. The extraction recovery was on average 60.0% for ebastine and 60.3% for carebastine.

Keywords

Column liquid chromatography–tandem mass spectrometry Ebastine Carebastine Human plasma 

References

  1. 1.
    Takanori H, Susumu I, Masashi M, Yoshiaki T, Toshihiko F, Hisashi M, Tetsuya K, Yoshihiko F (2002) J Pharmacol Exp Ther 300:298–304CrossRefGoogle Scholar
  2. 2.
    Bousquet J, Gaudano EM, Palma Carlos AG, Staudinger H (1999) Allergy 54:562–568CrossRefGoogle Scholar
  3. 3.
    Matsuda M, Mizuki Y, Terauchi Y (2001) J Chromatogr B Biomed Sci Appl 757:173–179CrossRefGoogle Scholar
  4. 4.
    Kang W, Liu K-H, Ryu J-Y, Shin J-G (2004) J Chromatogr B 813:75–80CrossRefGoogle Scholar
  5. 5.
    US Department of Health and Human Services Food and Drug Administration, Guidance for Industry: Bioanalytical Method validation, US Department of Health and Human Services: Rockville, MD, 2001. Website: http://www.fda.gov/cder/guidance/index.htm
  6. 6.
    State food and drug administration, The Guidance of bioavailability and bioequivalence study technique for chemistry drug in human (No. [H]GCL2-1). 2005. Website: http://www.sda.gov.cn/gsz05106/08.pdf
  7. 7.
    Taylor PJ (2005) Clin Biochem 38:328–334CrossRefGoogle Scholar

Copyright information

© Vieweg+Teubner | GWV Fachverlage GmbH 2009

Authors and Affiliations

  • Sheng Feng
    • 1
  • Ji Jiang
    • 1
  • Peng Wang
    • 1
  • Dongyang Liu
    • 1
  • Pei Hu
    • 1
  1. 1.Clinical Pharmacology Research CenterPeking Union Medical College Hospital and Chinese Academy of Medical SciencesBeijingPeople’s Republic of China

Personalised recommendations